Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Biochemistry

Succinate strikes

Nature volume 515, pages 350–351 (2014)Cite this article

Subjects

The high levels of tissue-damaging reactive oxygen species that arise during a stroke or heart attack have been shown to be generated through the accumulation of the metabolic intermediate succinate. See Letter p.431

When a stroke or a heart attack strikes, the tissue injury that occurs can be devastating. This damage to the brain or heart is a result of an initial starving of oxygen owing to blocked blood flow, followed by reoxygenation once blood flow is restored. Ischaemia reperfusion (IR) injury, as it is called, is a major health burden, and there are very few options to prevent it. On page 431 of this issue, Chouchani and colleagues1 present a finding that might inspire a new therapeutic approach. They reveal that succinate, an intermediate molecule normally formed during cellular respiration, is consistently elevated in ischaemic tissues, and that preventing this elevation is remarkably protective against IR injury in mouse models of stroke and heart attack. These findings add to those from other studies implicating succinate as an injurious metabolite, the limitation of which might have clinical utility2,3.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Succinate in inflammation and infarct.

References

  1. Chouchani, E. T. et al. Nature 515, 431–435 (2014).

    Article  ADS  CAS  Google Scholar 

  2. Tannahill, G. et al. Nature 496, 238–242 (2013).

    Article  ADS  CAS  Google Scholar 

  3. Mills, E. & O'Neill, L. A. J. Trends Cell Biol. 24, 313–320 (2014).

    Article  CAS  Google Scholar 

  4. Eltzschig, H. K. & Eckle, T. Nature Med. 17, 1391–1401 (2011).

    Article  CAS  Google Scholar 

  5. Hochachka, P. W. & Storey, K. B. Science 187, 613–621 (1975).

    Article  ADS  CAS  Google Scholar 

  6. Chouchani, E. T. et al. Nature Med. 19, 753–759 (2013).

    Article  CAS  Google Scholar 

  7. Shiomi, Y. et al. Inflamm. Bowel Dis. 17, 2261–2274 (2011).

    Article  Google Scholar 

  8. Kim, S. et al. PLoS ONE 9, e97501 (2014).

    Article  ADS  Google Scholar 

  9. Rubic, T. et al. Nature Immunol. 9, 1261–1269 (2008).

    Article  CAS  Google Scholar 

  10. Oyama, J. et al. Circulation 109, 784–789 (2004).

    Article  CAS  Google Scholar 

  11. Arslan, F. et al. Circulation 121, 80–90 (2010).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Luke A. J. O'Neill is in the School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, Ireland.,

    Luke A. J. O'Neill

Authors
  1. Luke A. J. O'Neill
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Luke A. J. O'Neill.

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

O'Neill, L. Succinate strikes. Nature 515, 350–351 (2014). https://doi.org/10.1038/nature13941

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nature13941

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research